Clinical Insights on Use of CAR-T Therapy
This segment highlights clinical experiences with ide-cel in the second-line setting, focusing on observed improvements in efficacy and quality of life, as well as challenges in administration
Video content above is prompted by the following:
- Can you share your experience with using ide-cel in the second-line setting?
- What improvements in efficacy and quality of life have you observed?
- What challenges have you faced in administering this treatment?
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
CCR Scores and Beyond: Precision Strategies for Treatment Intensification in Prostate Cancer
April 15th 2025Alvaro Martinez, MD discusses how emerging genomic risk stratification tools such as the clinical cell-cycle risk (CCR) score are transforming personalized prostate cancer treatment by enabling more nuanced assessments of metastasis risk and treatment intensification strategies beyond traditional NCCN risk groupings.
